Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12610885 | 0.73 | ESR2 (0.40) | GPR119KDM4EMAPK1ESR2ADORA1 | |
| SCHEMBL30213616 | 0.71 | KDM4E (0.42) | GPR119KDM4EMAPTTHRBMAPK1 | |
| SCHEMBL3505154 | 0.68 | ESR2 (0.45) | GPR119MAPK1ESR2ADORA1KMT2A | |
| SCHEMBL7420791 | 0.68 | ADORA1 (0.36) | GPR119ESR2ADORA1USP2SMN1; SMN2 | |
| SCHEMBL3806952 | 0.66 | KDM4E (0.35) | GPR119KDM4EMAPTTHRBUSP2 | |
| SCHEMBL2980997 | 0.66 | ESR2 (0.43) | GPR119KDM4EMAPTTHRBMAPK1 | |
| SCHEMBL17481737 | 0.66 | USP2 (0.41) | GPR119KDM4EMAPTTHRBMAPK1 | |
| SCHEMBL21708919 | 0.66 | USP2 (0.41) | GPR119MAPTMAPK1ESR2ADORA1 | |
| SCHEMBL2793465 | 0.65 | USP2 (0.37) | GPR119KDM4EMAPTTHRBESR2 | |
| SCHEMBL20690515 | 0.65 | ALDH1A1 (0.40) | GPR119KDM4EMAPTTHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| CN-101472892-A | Organic compounds | NOVARTIS AG (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | GPR119 2772/4885KDM4E 3571/4885MAPT 839/4885 |
| US-20110034462-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | GPR119 2772/4885KDM4E 3571/4885MAPT 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.